Submitted:
30 June 2026
Posted:
02 July 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Vinegar Production Method
- Alcoholic fermentation (or submerged fermentation) which takes place in anaerobic conditions under the action of the yeast Saccharomyces cerevisiae or Saccharomyces ellipsoideus, which transforms the fermentable sugars of the fruits into ethyl alcohol;
- (Acetic fermentation (or aerated fermentation) takes place in open air under the action of the acetic acid bacteria (Mycoderma aceti), which transforms the ethyl alcohol obtained in the previous phase into acetic acid.
2.2. Total Organics Acids Analysis of FVs
2.3. Total Polyphenols-Flavonoids Characterization and Total Acidity of FVs
2.4. DPPH Radical-Scavenging Antioxidant Activity
2.5. In Vivo FVs Experimental Protocol Treatment and Diet Composition
2.5.1. Experimented Wistar Rats Groups
- Group I or LSD group: Thirty Wistar rats were maintained ad libitum on laboratory synthetic chow pellets diet (LSD) is equivalent to 3.25 Kcal/g of food. LSD is provided by Carfil Quality, Beyntellus, Belgium; https://www.carfil.be). This synthetic diet contain: 47.4% carbohydrates, 25% proteins, 7.5% fat, contained vitamins and minerals substances. Group I represents the control group.
- Group II: This group consists of Wistar rats made obese by a high-fat diet (HFD), then made diabetic by intrapritoneal injection of streptozotocin (STZ). This experimental model, which involves feeding Wistar rats an HFD diet followed by a low-dose STZ injection, is a widely used and highly reliable experimental protocol for mimicking the natural progression and metabolic characteristics of type 2 diabetes (T2D) in humans [41]. This HFD diet contain: 35% carbohydrates, 20% proteins, 45% fat, contained vitamins and minerals substances. Thirty Wistar rats treated with a single injection of 45 mg/kg of STZ developed a T2D state [42]. HFD is equivalent to 4.75 Kcal/g of food. A HFD is defined as a dietary pattern characterized by a significant intake of fats, which has been associated with the development and maintenance of obesity due to its high caloric density and lower metabolic cost for fat storage compared to carbohydrates and proteins [43]. In this in vivo study, we used separately vinegars of Pomegranate vinegar (PGV); or Prickly Pear vinegar (PPV); or Apple vinegar (AV).
- Group III: This group contained 30 diabetic Wistar rats fed an HFD diet and treated separately with PGV, or PPV, or AV. The fruit vinegars (FVs) were administered daily via gastric intubation at a dose of 7 mL of FVs /kg body weight/day for 18 weeks. The dose of vinegar cocktail used in this study was set as the reference dose of apple cider vinegar (15 mL/day) which has shown a slimming effect in humans [44].
- Group IV: This group represents the placebo group, comprising 30 diabetic Wistar rats, which continued to be fed a high-fat diet and continuously received a 0.9% NaCl isotonic saline solution (placebo). It is important to clarify that FVs doses used in both in vivo and in vitro studies were established based on validated and published experimental protocols. Prior to this, we assessed the acute and subchronic toxicity of the vinegars according to the method described previously [45]. During this toxicity phase test (3.5 – 7 – 14 mL/kg p.c/day), we noted weight changes and the appearance of signs of toxicity such as behavioral disturbances in the cage, alopecia, skin rashes, lacrimation, or gastrointestinal manifestations like diarrhea. The mortality rate was also recorded. At the end of this phase, we established a concentration of 7 mL/kg body weight, primarily motivated by a balance between metabolic efficiency and gastrointestinal tolerance. In vitro study, experiments animals often adjust the acidity of the vinegar to a standard percentage, on average 0.5% w/v acetic acid [46].
2.5.2. Determination of Energy Expenditure, Basal Metabolism and Oxygen Consumption
2.6. In Vitro FVs Treatment on Viability-Cell Culture and Experimental Design
2.7. 3T3-L1 Cell Culture and Differentiation Adipogenesis Process
2.8. Oil Red O Staining
2.9. Triglyceride Level Analysis in 3T3-L1 Cells
2.10. Pro-Inflammatory Cytokines mRNA Expression
2.11. NF-κB Immunofluorescence Assay
2.12. Real-Time RT-PCR of the Primer Sequences
- 5’-ATGATATCGCCGCGCTCGTCGTC-3’, β-actin reverse: 5’- CTTCTTGGGCATGTAAAACT-3’; PPARγ forward: 5’- CCTGCGGAAGCCCTTTGGTGACTT-3’, PPARγ: reverse: 5’- TTCACGTTCAGCAAGCCTGGGC-3’; C/EBPα forward: 5’- GCAAAGCCAAGAAGTCGGTG-3’, C/EBPα reverse: 5’-
- AGGCGGTCATTGTCACTGGT- 3’; TNF-α forward: 5’-
- GGCAGGTCTACTTTGGAGTCATTGC-3’, TNF-α reverse: 5’-
- ACATTCGAGGCTCCAGTGAATTCG-3’; IL-1β forward: 5’- GGGCCTCAAAGGAAAGAATC-3’, IL-1β reverse: 5’-
- TACCAGTTGGGGAACTCTGC- 3’; IL-6 forward: 5’-
- GACAACCACGGCCTTCCCTA-3’, IL-6 reverse: 5’-
- GCCTCCGACTTGTGAAGTGGT-3’
2.13. Evaluation of Adiposity Index in Adipose Tissue Samples
2.14. Assessment of Plasma and Liver Biochemical Parameters
2.15. Determination of Protein, Glycogen and Lipid Levels in the Liver
2.16. Statistical Analysis
3. Results
3.1. Phytochemicals Analysis, Antioxidant Activity, Phenolic Profiles, and Organic Acid Contents in Pomegranate, Prickly Pear and Apple Vinegars
3.2. In Vivo Effects of Fruit Vinegars on the Body Adipose Tissue Distribution
3.3. In Vivo Effects of FVs on Caloric Intake, Energy Expenditure, Basal Metabolic Rate, Plasma and Hepatic Metabolic Status
3.4. In Vivo Effects of FVs on Systemic Inflammation and on Atherothromboembolic Risk
3.5. In Vitro Effects of FVs on Cell Viability and Cytotoxic
3.6. In Vitro Effects of FVs on Adipogenesis and Lipid Accumulation
3.7. In Vitro Effects of FVs on mRNA of PPARγ and C/EBPα Expression
3.8. In Vitro Effects of FVs on mRNA of Pro-Inflammatory Cytokine Expression
3.9. In Vitro Effects of FVs on NF-κB Nuclear Translocation
4. Discussion
- 1)
- Biological relevance of differences in polyphenol content and acidity in pomegranate vinegars versus prickly pear, and apple vinegars
- 2)
- Synergistic actions of epicatechin and quercetin to explain metabolic disorders attenuation
- 3)
- Exclusive presence of tannins in pomegranate vinegar could contribute to its more pronounced physiologic effects: The richness in tannins in pomegranate vinegar, particularly hydrolyzable tannins such as ellagitannins, it gives it many health benefits [69]. Indeed, Ellagitannins (Punicalagins) plays a crucial role in alleviates the symptoms of metabolic syndrome including blood pressure disorder, impaired glucose, dyslipidemia, ectopic fat deposition in intestine and liver. Besides, studies conducted on Sprague Dawley rats fed a high-fat diet have shown that ellagitannins exerts a significant modulating effect on mitochondrial gene expression, potentially influencing oxidative metabolism, especially against reactive oxygen species released during fatty acid oxidation in the mitochondrion [70]. The ellagitannins in pomegranate act as prebiotics by stimulating bacterial growth in the microbiota, including Enterobacteriaceae, the Bacteroides fragilis group, clostridia, bifidobacteria and lactobacilli [71]. It is important to emphasize those tannins and polyphenols are activated by the microbiota before entering the systemic circulation [72].
- The first target is linked to effects of FVs treatment via their flavonoid components on and calorie intake, energy expenditure, glycemia, insulin resistance, dyslipidemia and hepatic metabolic abnormalities.
- ii.
- The second target is related to FVs treatment on body adipose tissue distribution.
- iii.
- The third target is associated to FVs treatment on in vitro adipogenesis modulation via reduction of triglycerides accumulation in 3T3-L1 preadipocytes. Before discussing 3T3-L1 preadipocytes in vitro experimental section, it is important to emphasize that in vivo experimental section, we have demonstrated that FVs treatment has an anti-obesogenic effect on foods intake with a high patability value, which will be interesting to use FVs in hyperphagous subjects presenting eating disorders with bulimia attacks and cravings to reduce caloric intake. Concurrently, FVs treatment also significantly corrected hypertriglyceridemia and hypercholesterolemia associated with clearing accumulation lipid in the liver, and preventing the development of hepatic steatohepatitis. All together, the data of this study show that anthropometric and metabolic improvements reveal that FVs treatment is able in the long term to reverse insulin resistance and metabolic syndrome clusters. Furthermore, the HFD diet led to increased lipid accumulation (mainly triglycerides) in the liver, resulting in severe liver deterioration and an increase in liver mass, clearly indicating the development of morbid hepatic steatosis, mostly non-alcoholic fatty liver disease (NAFLD). Furthermore, FVs treatment lowered plasma homocysteine levels and, consequently, to avoid atherogenic risk. FVs treatment significantly reduced visceral fat mass; this has a positive impact on limiting the adipocytes size. Indeed, in this in vitro experimental study, we showed that FVs treatment significantly reduced lipid accumulation in 3T3-L1 preadipocytes compared to untreated 3T3-L1 control cells during cell differentiation, which may contribute to their anti-visceral obesity properties. Several studies have shown that triglycerides accumulation in the 3T3-L1 preadipocytes cytoplasm highlighted by oil red O indicates their differentiation into adipocytes [135]. Our in vitro data are in agreement to other anti-adipotogenic studies on vinegars treatment by triglycerides storage inhibition in 3T3-L1 preadipocytes and their differentiation into mature adipocytes [136,137]. In our study, we highlighted that pomegranate vinegar modulates adipocyte differentiation, which leads to lipid remodeling in adipocytes through the formation of lipid microdroplets, allowing for easier lipid degradation through lipolysis. This Adipose Tissue lipid remodelling is an important therapeutic property for metabolic disorders treatment observed in obesity and Type 2 diabetes. Previously, important studies have proven that the de novo lipogenesis of lipid microdroplets (mLD) has two interests cardiovascular protective target [138]. On the one hand, stimulating lipolysis by triglyceride lipases action with a larger surface area, on the other hand, preventing free fatty acids from cells lipotoxic [139]. This effect facilitates the fatty acids re-esterification and the mLD formation makes it possible to envisage a therapeutic target in the treatment of obesity and diabetes [140].
- iv.
- The fourth target is connected to FVs treatment on in vitro Adipogenesis Modulation via Down-Expression mRNA of PPARγ and C/EBPα.
- v.
- The fifth target is connected to FVs treatment on Adipogenesis Modulation via Down-Expression mRNA of Pro-inflammatory Cytokine and Inhibition of NF-κB nuclear translocation.
5. Conclusions
Institutional Review Board Statement
Informed Consent Statement
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Di Maio, G.; Tafuri, M.G.; Casillo, M.; Messina, A.; Allocca, S.; Villano, I.; Moscatelli, F.; Monda, A.; La Marra, M.; Monda, V. Physiological Regulation of Nutritional and Metabolic Biomarkers in Obesity: Implications for Precision Nutrition. Nutrients 2026, 18, 1014. [Google Scholar] [CrossRef] [PubMed]
- GBD 2021 Diabetes Collaborators. Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet 2023, 402, 203–234. [Google Scholar] [CrossRef] [PubMed]
- Cypess, A.M. Reassessing Human Adipose Tissue. N. Engl. J. Med. 2022, 386, 768–779. [Google Scholar] [CrossRef] [PubMed]
- Valenzuela, P.L.; Carrera-Bastos, P.; Castillo-García, A.; Lieberman, D.E.; Santos-Lozano, A.; Lucia, A. Obesity and the risk of cardiometabolic diseases. Nat. Rev. Cardiol. 2023, 20, 475–94. [Google Scholar] [CrossRef] [PubMed]
- Avgerinos, K.I.; Spyrou, N.; Mantzoros, C.S.; Dalamaga, M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism 2019, 92, 121–135. [Google Scholar] [CrossRef] [PubMed]
- Drolet, R.; Richard, C.; Sniderman, A.D.; Mailloux, J.; Fortier, M.; Huot, C.; Rhéaume, C.; Tchernof, A. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int. J. Obes. (Lond) 2008, 32, 283–91. [Google Scholar] [PubMed]
- Song, T.; Kuang, S. Adipocyte dedifferentiation in health and diseases. Clin. Sci. (Lond) . 2019, 133, 2107–2119. [Google Scholar] [CrossRef] [PubMed]
- Sul, H.S. Minireview: Pref-1: role in adipogenesis and mesenchymal cell fate. Mol. Endocrinol. 2009, 23, 1717–25. [Google Scholar] [CrossRef] [PubMed]
- Zebisch, K.; Voigt, V.; Wabitsch, M.; Brandsch, M. Protocol for effective differentiation of 3T3-L1 cells to adipocytes. Anal. Biochem. 2012, 425, 88–90. [Google Scholar] [CrossRef] [PubMed]
- Guru, A.; Issac, P.K.; Velayutham, M.; Saraswathi, N.T.; Arshad, A.; Arockiaraj, J. Molecular mechanism of down-regulating adipogenic transcription factors in 3T3-L1 adipocyte cells by bioactive anti-adipogenic compounds. Mol. Biol. Rep. 2021, 48, 743–761. [Google Scholar] [PubMed]
- Ghaben, A.L.; Scherer, P.E. Adipogenesis and metabolic health. Nat. Rev. Mol. Cell. Biol. 2019, 20, 242–258. [Google Scholar] [CrossRef] [PubMed]
- Castoldi, A.; Naffah de Souza, C.; Câmara, N.O.; Moraes-Vieira, P.M. The Macrophage Switch in Obesity Development. Front. Immunol. 2016, 6, 637. [Google Scholar] [CrossRef] [PubMed]
- Russo, L.; Lumeng, C.N. Properties and functions of adipose tissue macrophages in obesity. Immunology 2018, 155, 407–417. [Google Scholar] [CrossRef] [PubMed]
- Xu, S.; Lu, F.; Gao, J.; Yuan, Y. Inflammation-mediated metabolic regulation in adipose tissue. Obes. Rev. 2024, 25, e13724. [Google Scholar] [PubMed]
- Horwitz, A.; Birk, R. Adipose Tissue Hyperplasia and Hypertrophy in Common and Syndromic Obesity-The Case of BBS Obesity. Nutrients 2023, 15, 3445. [Google Scholar] [PubMed]
- Baker, R.G.; Hayden, M.S.; Ghosh, S. NF-κB, inflammation, and metabolic disease. Cell. Metab. 2011, 13, 11–22. [Google Scholar] [PubMed]
- Celletti, F.; Farrar, J.; De Regil, L. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA 2026, 335, 434–438. [Google Scholar] [CrossRef] [PubMed]
- Yanovski, S.Z.; Yanovski, J.A. Approach to Obesity Treatment in Primary Care: A Review. JAMA Intern. Med. 2024, 184, 818–829. [Google Scholar] [PubMed]
- Jackson, V.M.; Breen, D.M.; Fortin, J.P.; Liou, A.; Kuzmiski, J.B.; Loomis, A.K.; Rives, M.L.; Shah, B.; Carpino, P.A. Latest approaches for the treatment of obesity. Expert. Opin. Drug. Discov. 2015, 10, 825–39. [Google Scholar] [CrossRef] [PubMed]
- Yuan, X.; Wang, T.; Sun, L.; Qiao, Z.; Pan, H.; Zhong, Y.; Zhuang, Y. Recent advances of fermented fruits: A review on strains, fermentation strategies, and functional activities. Food Chem. X. 2024, 22, 101482. [Google Scholar] [CrossRef] [PubMed]
- Xia, T.; Zhang, B.; Duan, W.; Zhang, J.; Wang, M. Nutrients and bioactive components from vinegar: A fermented and functional food. J. Funct. Foods 2020, 64, 103681. [Google Scholar] [CrossRef]
- Khalifa, S.A.M.; El-Shabasy, R.M.; Tahir, H.E.; Abo-Atya, D.M.; Saeed, A.; Abolibda, T.Z.; Guo, Z.; Zou, X.; Zhang, D.; Du, M.; et al. Vinegar - a beneficial food additive: production, safety, possibilities, and applications from ancient to modern times. Food Funct. 2024, 15, 10262–10282. [Google Scholar] [PubMed]
- Chen, H.; Chen, T.; Giudici, P.; Chen, F. Vinegar Functions on Health: Constituents, Sources, and Formation Mechanisms. Compr. Rev. Food Sci. Food Saf. 2016, 15, 1124–1138. [Google Scholar] [CrossRef] [PubMed]
- Kondo, T.; Kishi, M.; Fushimi, T.; Ugajin, S.; Kaga, T. Vinegar intake reduces body weight, body fat mass, and serum triglyceride levels in obese Japanese subjects. Biosci. Biotechnol. Biochem. 2009, 73, 1837–43. [Google Scholar] [CrossRef] [PubMed]
- Yildiz, E. Characterization of Fruit Vinegars via Bioactive and Organic Acid Profile Using Chemometrics. Foods 2023, 12, 3769. [Google Scholar] [CrossRef] [PubMed]
- Billowria, K.; Ali, R.; Rangra, N.K.; Kumar, R.; Chawla, P.A. Bioactive Flavonoids: A Comprehensive Review on Pharmacokinetics and Analytical Aspects. Crit. Rev. Anal. Chem. 2024, 54, 1002–1016. [Google Scholar] [PubMed]
- Ousaaid, D.; Mechchate, H.; Laaroussi, H.; Hano, C.; Bakour, M.; El Ghouizi, A.; Conte, R.; Lyoussi, B.; El Arabi, I. Fruits Vinegar: Quality Characteristics, Phytochemistry, and Functionality. Molecules 2021, 27, 222. [Google Scholar] [CrossRef] [PubMed]
- Jin, C.H.; Zhang, Y.Z.; Wu, F.H.; Wu, C.L.; Wang, P.; Feng, W.; Liang, L.M.; Xu, W.J.; Sun, X.T.; Liu, X.Q.; et al. Advances in the research on phenolic acids and flavonoids in vinegar: Sources, formation and degradation mechanisms, and functional properties. Food Res. Int. 2025, 222, 117702. [Google Scholar] [CrossRef] [PubMed]
- Hadi, A.; Pourmasoumi, M.; Najafgholizadeh, A.; Clark, C.C.T.; Esmaillzadeh, A. The effect of apple cider vinegar on lipid profiles and glycemic parameters: a systematic review and meta-analysis of randomized clinical trials. BMC Complement Med. Ther. 2021, 21, 179. [Google Scholar] [CrossRef] [PubMed]
- Tehrani, S.D.; Keshani, M.; Rouhani, M.H.; Moallem, S.A.; Bagherniya, M.; Sahebkar, A. The Effects of Apple Cider Vinegar on Cardiometabolic Risk Factors: A Systematic Review and Meta-analysis of Clinical Trials. Curr. Med. Chem. 2025, 32, 2257–2274. [Google Scholar] [CrossRef] [PubMed]
- Bouazza, A.; Bitam, A.; Amiali, M.; Bounihi, A.; Yargui, L.; Koceir, E.A. Effect of fruit vinegars on liver damage and oxidative stress in high-fat-fed rats. Pharm. Biol. 2016, 54, 260–5. [Google Scholar] [PubMed]
- Bounihi, A.; Bitam, A.; Bouazza, A.; Yargui, L.; Koceir, E.A. Fruit vinegars attenuate cardiac injury via anti-inflammatory and anti-adiposity actions in high-fat diet-induced obese rats. Pharm. Biol. 2017, 55, 43–52. [Google Scholar] [PubMed]
- Eghbali, S.; Askari, S.F.; Avan, R.; Sahebkar, A. Therapeutic Effects of Punica granatum (Pomegranate): An Updated Review of Clinical Trials. J. Nutr. Metab. 2021, 2021, 5297162. [Google Scholar] [CrossRef] [PubMed]
- Patocka, J.; Bhardwaj, K.; Klimova, B.; Nepovimova, E.; Wu, Q.; Landi, M.; Kuca, K.; Valis, M.; Wu, W. Malus domestica: A Review on Nutritional Features, Chemical Composition, Traditional and Medicinal Value. Plants 2020, 9, 1408. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Chang, H.; Shao, S.; Zhao, L.; Zhang, R.; Zhang, S. Anthocyanins from Opuntia ficus-indica Modulate Gut Microbiota Composition and Improve Short-Chain Fatty Acid Production. Biology 2022, 11, 1505. [Google Scholar] [PubMed]
- Viana, R.O.; Magalhães-Guedes, K.T.; Braga, R.A., Jr.; Dias, D.R.; Schwan, R.F. Fermentation process for production of apple-based kefir vinegar: microbiological, chemical and sensory analysis. Braz. J. Microbiol. 2017, 48, 592–601. [Google Scholar] [CrossRef] [PubMed]
- Kašpar, M.; Bajer, T.; Bajerová, P.; Česla, P. Comparison of Phenolic Profile of Balsamic Vinegars Determined Using Liquid and Gas Chromatography Coupled with Mass Spectrometry. Molecules 2022, 27, 1356. [Google Scholar] [CrossRef] [PubMed]
- Pérez, M.; Dominguez-López, I.; Lamuela-Raventós, R.M. The Chemistry Behind the Folin-Ciocalteu Method for the Estimation of (Poly) phenol Content in Food: Total Phenolic Intake in a Mediterranean Dietary Pattern. J. Agric. Food. Chem. 2023, 71, 17543–17553. [Google Scholar] [PubMed]
- Mammen, D.; Daniel, M. A critical evaluation on the reliability of two aluminum chloride chelation methods for quantification of flavonoids. Food Chem. 2012, 135, 1365–8. [Google Scholar] [CrossRef] [PubMed]
- Tatarczak-Michalewska, M.; Flieger, J. Application of High-Performance Liquid Chromatography with Diode Array Detection to Simultaneous Analysis of Reference Antioxidants and 1,1-Diphenyl-2-picrylhydrazyl (DPPH) in Free Radical Scavenging Test. Int. J. Environ. Res. Public Heal. 2022, 19, 8288. [Google Scholar]
- Leguina-Ruzzi, A.; Ortiz, R.; Velarde, V. The streptozotocin-high fat diet induced diabetic mouse model exhibits severe skin damage and alterations in local lipid mediators. Biom. J. 2018, 41, 328–332. [Google Scholar] [CrossRef]
- Furman, B.L. Streptozotocin-induced diabetic models in mice and rats. Curr. Protoc. Pharmacol. 2015, 70, 5.47.1–5.47.20. [Google Scholar] [PubMed]
- Licholai, J.A.; Nguyen, K.P.; Fobbs, W.C.; Schuster, C.J.; Ali, M.A.; Kravitz, A.V. Why Do Mice Overeat High-Fat Diets? How High-Fat Diet Alters the Regulation of Daily Caloric Intake in Mice. Obesity 2018, 26, 1026–1033. [Google Scholar] [PubMed]
- Kondo, T.; Kishi, M.; Fushimi, T.; Ugajin, S.; Kaga, T. Vinegar intake reduces body weight, body fat mass, and serum triglyceride levels in obese Japanese subjects. Biosci. Biotechnol. Biochem. 2009, 73, 1837–43. [Google Scholar] [CrossRef] [PubMed]
- Suganthy, N.; Karthikeyan, K.; Archunan, G.; Pandian, S.K.; Devi, K.P. Safety and toxicological evaluation of Rhizopora mucronata (a mangrove from Vellar estuary, India): assessment of mutagenicity, genotoxicity and in vivo acute toxicity. Mol. Biol. Rep. 2014, 41, 1355–71. [Google Scholar] [CrossRef] [PubMed]
- Olas, B. Pro-Health Potential of Fruit Vinegars and Oxymels in Various Experimental Models. Int. J. Mol. Sci. 2024, 26, 7. [Google Scholar] [CrossRef] [PubMed]
- McNab, B.K. An analysis of the factors that influence the level and scaling of mammalian BMR. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2008, 151, 5–28. [Google Scholar] [CrossRef] [PubMed]
- Frayn, K.N. Calculation of substrate oxidation rates in vivo from gaseous exchange. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1983, 55, 628–634. [Google Scholar] [CrossRef] [PubMed]
- Cave, E.; Crowther, N.J. The Use of 3T3-L1 Murine Preadipocytes as a Model of Adipogenesis. Methods Mol. Biol. 2019, 1916, 263–272. [Google Scholar] [PubMed]
- Du, J.; Zhao, L.; Kang, Q.; He, Y.; Bi, Y. An optimized method for Oil Red O staining with the salicylic acid ethanol solution. Adipocyte 2023, 12, 2179334. [Google Scholar] [CrossRef] [PubMed]
- Swaggerty, C.L.; Pevzner, I.Y.; Kaiser, P.; Kogut, M.H. Profiling pro-inflammatory cytokine and chemokine mRNA expression levels as a novel method for selection of increased innate immune responsiveness. Vet. Immunol. Immunopathol. 2008, 126, 35–42. [Google Scholar] [PubMed]
- Kumar, R.P.; Abraham, A. Inhibition of LPS induced pro-inflammatory responses in RAW 264.7 macrophage cells by PVP-coated naringenin nanoparticle via down regulation of NF-kappaB/P38MAPK mediated stress signaling. Pharmacol. Rep. 2017, 69, 908–915. [Google Scholar]
- Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–8. [Google Scholar] [PubMed]
- Leopoldo, A.S.; Lima-Leopoldo, A.P.; Nascimento, A.F.; Luvizotto, R.A.; Sugizaki, M.M.; Campos, D.H.; da Silva, D.C.; Padovani, C.R.; Cicogna, A.C. Classification of different degrees of adiposity in sedentary rats. Braz. J. Med. Biol. Res. 2016, 49, e5028. [Google Scholar] [CrossRef] [PubMed]
- Chang, Y.; Ryu, S.; Sung, E.; Jang, Y. Higher concentrations of alanine amino transferase within the reference interval predict nonalcoholic fatty liver disease. Clin. Chem. 2007, 53, 686–92. [Google Scholar] [PubMed]
- Engl, J.; Sturm, W.; Sandhofer, A.; Kaser, S.; Tschoner, A.; Tatarczyk, T.; Weiss, H.; Tilg, H.; Patsch, J.R.; Ebenbichler, C.F. Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur. J. Clin. Invest. 2008, 38, 238–44. [Google Scholar] [CrossRef] [PubMed]
- Antunes, L.C.; Elkfury, J.L.; Jornada, M.N.; Foletto, K.C.; Bertoluci, M.C. Validation of HOMA-IR in a model of insulin-resistance induced by a high-fat diet in Wistar rats. Arch. Endocrinol. Metab. 2016, 60, 138–42. [Google Scholar] [PubMed]
- Burdge, G.C.; Wright, P.; Jones, A.E.; Wootton, S.A. A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction. Br. J. Nutr. 2000, 84, 781–7. [Google Scholar] [PubMed]
- Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248–54. [Google Scholar] [CrossRef] [PubMed]
- Folch, J.; Lees, M.; Sloane Stanley, G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226, 497–509. [Google Scholar] [CrossRef] [PubMed]
- Chan, T.M.; Exton, J.H. A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal. Biochem. 1976, 71, 96–105. [Google Scholar] [CrossRef] [PubMed]
- Permana, D. The Pomegranate Grower’s Handbook. 2024. 159p. In dependently published; ISBN -13: 979-8336849677.
- Virgen-Carrillo, C.A.; Mojica, L. Bioactive Compounds From Pomegranate: A Systematic Review of Mechanistic Insights for the Management of Cardiometabolic Risk Factors. J. Food Sci. 2025, 90, e70358. [Google Scholar] [CrossRef] [PubMed]
- Leyva-Soto, A.; Alejandra Chavez-Santoscoy, R.; Porras, O.; Hidalgo-Ledesma, M.; Serrano-Medina, A.; Alejandra Ramírez-Rodríguez, A.; Alejandra Castillo-Martinez, N. Epicatechin and quercetin exhibit in vitro antioxidant effect, improve biochemical parameters related to metabolic syndrome, and decrease cellular genotoxicity in humans. Food Res. Int. 2021, 142, 110101. [Google Scholar] [CrossRef] [PubMed]
- Nichols, M.; Zhang, J.; Polster, B.M.; Elustondo, P.A.; Thirumaran, A.; Pavlov, E.V.; Robertson, G.S. Synergistic neuroprotection by epicatechin and quercetin: Activation of convergent mitochondrial signaling pathways. Neuroscience 2015, 308, 75–94. [Google Scholar] [CrossRef] [PubMed]
- Montero, M.; Lobatón, C.D.; Hernández-Sanmiguel, E.; Santodomingo, J.; Vay, L.; Moreno, A.; Alvarez, J. Direct activation of the mitochondrial calcium uniporter by natural plant flavonoids. Biochem J. 2004, 384, 19–24. [Google Scholar] [CrossRef] [PubMed]
- Williamson, G.; Sheedy, K. Effects of Polyphenols on Insulin Resistance. Nutrients 2020, 12, 3135. [Google Scholar] [CrossRef] [PubMed]
- Cunningham, P.; Afzal-Ahmed, I.; Naftalin, R.J. Docking studies show that D-glucose and quercetin slide through the transporter GLUT1. J. Biol. Chem. 2006, 281, 5797–803. [Google Scholar] [CrossRef] [PubMed]
- Heber, D. Pomegranate Ellagitannins. In Herbal Medicine: Biomolecular and Clinical Aspects;Chapter 10, 2nd edition; Benzie, I.F.F., Wachtel-Galor, S., Eds.; CRC Press/Taylor & Francis: Boca Raton (FL), 2011. [Google Scholar]
- Cheng, H.S.; Goh, B.H.; Phang, S.C.W.; Amanullah, M.M.; Ton, S.H.; Palanisamy, U.D.; Abdul Kadir, K.; Tan, J.B.L. Pleiotropic ameliorative effects of ellagitannin geraniin against metabolic syndrome induced by high-fat diet in rats. Nutrition 2020, 79-80, 110973. [Google Scholar] [CrossRef] [PubMed]
- Li, Z.; Summanen, P.H.; Komoriya, T.; Henning, S.M.; Lee, R.P.; Carlson, E.; Heber, D.; Finegold, S.M. Pomegranate ellagitannins stimulate growth of gut bacteria in vitro: Implications for prebiotic and metabolic effects. Anaerobe 2015, 34, 164–8. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Ho, L.; Faith, J.; Ono, K.; Janle, E.M.; Lachcik, P.J.; Cooper, B.R.; Jannasch, A.H.; D'Arcy, B.R.; Williams, B.A.; et al. Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease β-amyloid oligomerization. Mol. Nutr. Food Res. 2015, 59, 1025–40. [Google Scholar] [PubMed]
- Sahar, S.A.; Soltan; Shehata, M.M.E.M. Antidiabetic and Hypocholesrolemic Effect of Different Types of Vinegar in Rats. Life Sci. J. 2012, 9, 2141–2151. [Google Scholar]
- Darzi, J.; Frost, G.S.; Montaser, R.; Yap, J.; Robertson, M.D. Influence of the tolerability of vinegar as an oral source of short-chain fatty acids on appetite control and food intake. Int. J. Obes. (Lond) . 2014, 38, 675–81. [Google Scholar] [PubMed]
- Hasan, F.; Hamilton, K.; Angadi, S.; Kranz, S. The Effects of Vinegar/Acetic Acid Intake on Appetite Measures and Energy Consumption: A Systematic Literature Review. Curr. Dev. Nutr. 2022, 6 (Suppl 1), 285. [Google Scholar] [CrossRef]
- Tazoe, H.; Otomo, Y.; Kaji, I.; Tanaka, R.; Karaki, S.I.; Kuwahara, A. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J. Physiol. Pharmacol. 2008, 59, 251–262. [Google Scholar] [PubMed]
- Tazoe, H.; Otomo, Y.; Karaki, S.; Kato, I.; Fukami, Y.; Terasaki, M.; Kuwahara, A. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed. Res. 2009, 30, 149–156. [Google Scholar] [CrossRef] [PubMed]
- Karaki, S.; Tazoe, H.; Hayashi, H.; Kashiwabara, H.; Tooyama, K.; Suzuki, Y.; Kuwahara, A. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J. Mol. Histol. 2008, 39, 135–42. [Google Scholar] [PubMed]
- Brown, A.J.; Goldsworthy, S.M.; Barnes, A.A.; Eilert, M.M.; Tcheang, L.; Daniels, D.; Muir, A.I.; Wigglesworth, M.J.; Kinghorn, I.; Fraser, N.J.; et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278, 11312–9. [Google Scholar] [CrossRef] [PubMed]
- Bellisle, F.; Louis-Sylvestre, J.; Demozay, F.; Blazy, D.; Le Magnen, J. Cephalic phase of insulin secretion and food stimulation in humans: a new perspective. Am. J. Physiol. 1985, 249, E639–E645. [Google Scholar] [CrossRef] [PubMed]
- Lucas, F.; Bellisle, F.; Di Maio, A. Spontaneous insulin fluctuations and the preabsorptive insulin response to food ingestion in humans. Physiol. Behav. 1987, 40, 631–636. [Google Scholar] [CrossRef] [PubMed]
- Wicks, D.; Wright, J.; Rayment, P.; Spiller, R. Impact of bitter taste on gastric motility. Eur. J. Gastroenterol. Hepatol. 2005, 17, 961–965. [Google Scholar] [CrossRef] [PubMed]
- Stern, R.M.; Jokerst, M.D.; Levine, M.E.; Koch, K.L. The stomach’s response to unappetizing food: cephalic-vagal effects on gastric myoelectric activity. Neurogastroenterol. Motil. 2001, 13, 151–154. [Google Scholar] [PubMed]
- Lin, H.C.; Doty, J.E.; Reedy, T.J.; Meyer, J.H. Inhibition of Gastric Emptying by Acids Depends on pH, Titratable Acidity, and Length of Intestine Exposed to Acid. Am. J. Physiol. 1990, 259, 1025. [Google Scholar] [CrossRef]
- Romero-Juárez, P.A.; Visco, D.B.; Manhães-de-Castro, R.; Urquiza-Martínez, M.V.; Saavedra, L.M.; González-Vargas, M.C.; Mercado-Camargo, R.; Aquino, J.S.; Toscano, A.E.; Torner, L.; et al. Dietary flavonoid kaempferol reduces obesity-associated hypothalamic microglia activation and promotes body weight loss in mice with obesity. Nutr. Neurosci. 2023, 26, 25–39. [Google Scholar] [PubMed]
- Belfort-DeAguiar, R.; Seo, D. Food Cues and Obesity: Overpowering Hormones and Energy Balance Regulation. Curr. Obes. Rep. 2018, 7, 122–129. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Xu, Y. The central melanocortin system and human obesity. J. Mol. Cell. Biol. 2020, 12, 785–797. [Google Scholar] [CrossRef] [PubMed]
- Timper, K.; Brüning, J.C. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis. Model Mech. 2017, 10, 679–689. [Google Scholar] [CrossRef] [PubMed]
- Dulloo, A.G. The search for compounds that stimulate thermogenesis in obesity management: from pharmaceuticals to functional food ingredients. Obes. Rev. 2011, 12, 866–83. [Google Scholar] [CrossRef] [PubMed]
- Ichikawa, M.; Ohta, M.; Kanai, S.; Yoshida, Y.; Takano, S.; Ueoka, T.; Takahashi, T.; Kimoto, K.; Funakoshi; A. Miyasaka, K. Bitter melon malt vinegar increases daily energy turnover in rats. J. Nutr. Sci. Vitaminol. 2003, 49, 428–33. [Google Scholar] [CrossRef] [PubMed]
- Seok, H.; Lee, J.Y.; Park, E.M.; Park, S.E.; Lee, J.H.; Lim, S.; Lee, B.; Kang, E.S.; Lee, H.C.; Cha, B.S. Balsamic Vinegar Improves High Fat-Induced Beta Cell Dysfunction Via Beta Cell ABCA1. Diabetes Metab. J. 2012, 36, 275–279. [Google Scholar] [CrossRef] [PubMed]
- Gu, X.; Zhao, H.; Sui, Y.; Guan, J.; Chan, J.C.N.; Tong, P.C.Y. White Rice Vinegar Improves Pancreatic Beta-Cell Function and Fatty Liver in Streptozotocin-Induced Diabetic Rats. Acta. Diabetol. 2010, 49, 185. [Google Scholar] [PubMed]
- Ostman, E.; Granfeldt, Y.; Persson, L.; Björck, I. Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects. Eur. J. Clin. Nutr. 2005, 59, 983–8. [Google Scholar] [CrossRef] [PubMed]
- Brighenti, F.; Castellani, G.; Benini, L.; Casiraghi, M.C.; Leopardi, E.; Crovetti, R.; Testolin, G. Effect of neutralized and native vinegar on blood glucose and acetate responses to a mixed meal in healthy subjects. Eur. J. Clin. Nutr. 1995, 49, 242–7. [Google Scholar] [PubMed]
- Johnston, C.S.; Buller, A.J. Vinegar and peanut products as complementary foods to reduce postprandial glycaemia. J. Am. Diet. Assoc. 2005, 105, 1939–1942. [Google Scholar] [PubMed]
- Liljeberg, H.; Bjorck, I. Delayed gastric emptying rate may explain improved glycaemia in healthy subjects to a starchy meal with added vinegar. Eur. J. Clin. Nutr. 1998, 52, 368–371. [Google Scholar] [CrossRef] [PubMed]
- Liljeberg, H.G.M.; Bjorck, I.M.E. Delayed gastric emptying rate as a potential mechanism for lowered glycaemia after eating sourdough bread: studies in humans and rats using test products with added organic acids or an organic salt. Am. J. Clin. Nutr. 1996, 64, 886–893. [Google Scholar] [PubMed]
- Sugiyama, M.; Tang, A.C.; Wakaki, Y.; Koyama, W. Glycaemic index of single and mixed meal foods among common Japanese foods with white rice as a reference food. Eur. J. Clin. Nutr. 2003, 57, 743–752. [Google Scholar] [PubMed]
- Santos, H.O.; de Moraes, W.M.A.M.; da Silva, G.A.R.; Prestes, J.; Schoenfeld, B.J. Vinegar (acetic acid) intake on glucose metabolism: A narrative review. Clin. Nutr. ESPEN 2019, 32, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Mitrou, P.; Petsiou, E.; Papakonstantinou, E.; Maratou, E.; Lambadiari, V.; Dimitriadis, P.; Spanoudi, F.; Raptis, S.A.; Dimitriadis, G. The role of acetic acid on glucose uptake and blood flow rates in the skeletal muscle in humans with impaired glucose tolerance. Eur. J. Clin. Nutr. 2015, 69, 734e9. [Google Scholar] [CrossRef]
- Seyidoglu, N.; Karakçı, D.; Ergin Eğritağ, H.; Yıkmış, S. A New Alternative Nutritional Source Hawthorn Vinegar: How It Interacts with Protein, Glucose and GLP-1. Nutrients 2024, 16, 2163. [Google Scholar] [CrossRef] [PubMed]
- Sakakibara, S.; Yamauchi, T.; Oshima, Y.; Tsukamoto, Y.; Kadowaki, T. Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A(y) mice. Biochem. Biophys. Res. Commun. 2006, 344, 597–604. [Google Scholar] [PubMed]
- Johnston, C.S.; White, A.M.; Kent, S.M. Preliminary evidence that regular vinegar ingestion favorably influences hemoglobin A1c values in individuals with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2009, 84, e15-7. [Google Scholar] [CrossRef] [PubMed]
- Gheflati, A.; Bashiri, R.; Ghadiri-Anari, A.; Reza, J.Z.; Kord, M.T.; Nadjarzadeh, A. The effect of apple vinegar consumption on glycemic indices, blood pressure, oxidative stress, and homocysteine in patients with type 2 diabetes and dyslipidemia: A randomized controlled clinical trial. Clin. Nutr. ESPEN. 2019, 33, 132–138. [Google Scholar] [CrossRef] [PubMed]
- Brighenti, F.; Castellani, G.; Benini, L.; Casiraghi, M.C.; Leopardi, E.; Crovetti, R.; Testolin, G. Effect of neutralized and native vinegar on blood glucose and acetate responses to a mixed meal in healthy subjects. Eur. J. Clin. Nutr. 1995, 49, 242–7. [Google Scholar] [PubMed]
- Cheng, L.J.; Jiang, Y.; Wu, V.X.; Wang, W. A systematic review and meta-analysis: Vinegar consumption on glycaemic control in adults with type 2 diabetes mellitus. J. Adv. Nurs. 2020, 76, 459–474. [Google Scholar] [PubMed]
- Ogawa, N.; Satsu, H.; Watanabe, H.; Fukaya, M.; Tsukamoto, Y.; Miyamoto, Y.; Shimizu, M. Acetic acid suppresses the increase in disaccharidase activity that occurs during culture of Caco-2 cells. J. Nutr. 2000, 130, 507–513. [Google Scholar] [CrossRef] [PubMed]
- Fushimi, T.; Tayama, K.; Fukaya, M.; Kitakoshi, K.; Nakai, N.; Tsukamoto, Y.; Sato, Y. Acetic acid feeding enhances glycogen repletion in liver and skeletal muscle of rats. J. Nutr. 2001, 131, 1973–1977. [Google Scholar] [CrossRef] [PubMed]
- Johnston, C.S.; Kim, C.M.; Buller, A.J. Vinegar improves insulin sensitivity to a high- carbohydrate meal in subjects with insulin resistance or type 2 diabetes. Diabetes Care 2004, 27, 281–2. [Google Scholar] [CrossRef] [PubMed]
- Seyidoglu, N.; Karakçı, D.; Ergin Eğritağ, H.; Yıkmış, S. A New Alternative Nutritional Source Hawthorn Vinegar: How It Interacts with Protein, Glucose and GLP-1. Nutrients 2024, 16, 2163. [Google Scholar] [CrossRef] [PubMed]
- Doan, K.V.; Ko, C.M.; Kinyua, A.W.; Yang, D.J.; Choi, Y.H.; Oh, I.Y.; Nguyen, N.M.; Ko, A.; Choi, J.W.; Jeong, Y.; et al. Gallic acid regulates body weight and glucose homeostasis through AMPK activation. Endocrinology 2015, 156, 157–68. [Google Scholar] [CrossRef] [PubMed]
- Liao, C.C.; Ou, T.T.; Wu, C.H.; Wang, C.J. Prevention of diet-induced hyperlipidemia and obesity by caffeic acid in C57BL/6 mice through regulation of hepatic lipogenesis gene expression. J. Agric. Food Chem. 2013, 61, 11082–8. [Google Scholar] [PubMed]
- Edwards, M.; Mohiuddin, S.S. Biochemistry, Lipolysis. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2026, 2023; p. 17. [Google Scholar]
- Zacharewicz, E.; Hesselink, M.K.C.; Schrauwen, P. Exercise counteracts lipotoxicity by improving lipid turnover and lipid droplet quality. J. Intern. Med. 2018, 284, 505–518. [Google Scholar] [CrossRef] [PubMed]
- Russell, A.P. Lipotoxicity: the obese and endurance-trained paradox. Int. J. Obes. Relat. Metab. Disord. 2004, 4, S66–71. [Google Scholar] [CrossRef]
- Ali, Z.; Ma, H.; Rashid, M.T.; Ayim, I.; Wali, A. Reduction of body weight, body fat mass, and serum leptin levels by addition of new bever age in normal diet of obese subjects. J. Food Biochem 2018, e12554. [Google Scholar]
- Frost, G.; Sleeth, M.L.; Sahuri-Arisoylu, M.; Lizarbe, B.; Cerdan, S.; Brody, L.; Anastasovska, J.; Ghourab, S.; Hankir, M.; Zhang, S.; et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 2014, 5, 3611. [Google Scholar] [CrossRef] [PubMed]
- Hadi, A.; Pourmasoumi, M.; Najafgholizadeh, A.; Clark, C.C.T.; Esmaillzadeh, A. The effect of apple cider vinegar on lipid profiles and glycemic parameters: a systematic review and meta-analysis of randomized clinical trials. BMC Complement Med. Ther. 2021, 21, 179. [Google Scholar] [CrossRef] [PubMed]
- Kondo, T.; Kishi, M.; Fushimi, T.; Kaga, T. Acetic acid upregulates the expression of genes for fatty acid oxidation enzymes in liver to suppress body fat accumulation. J. Agric. Food Chem. 2009, 57, 5982–6. [Google Scholar] [CrossRef] [PubMed]
- Lim, J.; Henry, C.J.; Haldar, S. Vinegar as a functional ingredient to improve postprandial glycemic control-human intervention findings and molecular mechanisms. Mol. Nutr. Food Res. 2016, 60, 1837–49. [Google Scholar] [PubMed]
- Tan, J.T.M.; Nankivell, V.A.; Bilu, C.; Shemesh, T.; Nicholls, S.J.; Zimmet, P.; Kronfeld-Schor, N.; Brown, A.; Bursill, C.A. High-Energy Diet and Shorter Light Exposure Drives Markers of Adipocyte Dysfunction in Visceral and Subcutaneous Adipose Depots of Psammomys obesus. Int. J. Mol. Sci. 2019, 20, 6291. [Google Scholar] [CrossRef] [PubMed]
- Booth, A.D.; Magnuson, A.M.; Fouts, J.; Wei, Y.; Wang, D.; Pagliassotti, M.J.; Foster, M.T. Subcutaneous adipose tissue accumulation protects systemic glucose tolerance and muscle metabolism. Adipocyte 2018, 7, 261–272. [Google Scholar] [CrossRef] [PubMed]
- Coulter, A.A.; Greenway, F.L.; Ramanathan, G.; Hubbard, J.R.; Rebello, C.J. Phytocompounds That Target White Adipose Tissue for Weight Loss: A Review Spanning From Ucp1 Induction in Rodents to Human Clinical Trials. Obes. Rev. 2026, 15, e70173. [Google Scholar] [CrossRef]
- Hu, J.; Kyrou, I.; Tan, B.K.; Dimitriadis, G.K.; Ramanjaneya, M.; Tripathi, G.; Patel, V.; James, S.; Kawan, M.; Chen, J.; et al. Short-Chain Fatty Acid Acetate Stimulates Adipogenesis and Mitochondrial Biogenesis via GPR43 in Brown Adipocytes. Endocrinology 2016, 157, 1881–94. [Google Scholar] [CrossRef] [PubMed]
- John, C.M.; Arockiasamy, S. Sinapic acid prevents adipogenesis by regulating transcription factors and exerts an anti-ROS effect by modifying the intracellular anti-oxidant system in 3T3-L1 adipocytes. Iran. J. Basic Med. Sci. 2022, 25, 611–620. [Google Scholar] [PubMed]
- Castagna, A.; Ferro, Y.; Noto, F.R.; Bruno, R.; Aragao Guimaraes, A.; Pujia, C.; Mazza, E.; Maurotti, S.; Montalcini, T.; Pujia, A. Effect of Apple Cider Vinegar Intake on Body Composition in Humans with Type 2 Diabetes and/or Overweight: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2025, 17, 3000. [Google Scholar] [CrossRef] [PubMed]
- Grahame Hardie, D. AMP-Activated Protein Kinase: A Master Switch in Glucose and Lipid Metabolism. Rev. Endocr. Metab. Disord. 2004, 5, 119–125. [Google Scholar] [CrossRef]
- Yamashita, H.; Fujisawa, K.; Ito, E.; Idei, S.; Kawaguchi, N.; Kimoto, M.; Hiemori, M.; Tsuji, H. Improvement of Obesity and Glucose Tolerance by Acetate in Type 2 Diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) Rats. Biosci. Biotechnol. Biochem. 2007, 71, 1236–1243. [Google Scholar] [CrossRef] [PubMed]
- Patocka, J.; Bhardwaj, K.; Klimova, B.; Nepovimova, E.; Wu, Q.; Landi, M.; Kuca, K.; Valis, M.; Wu, W. Malus domestica: A Review on Nutritional Features, Chemical Composition, Traditional and Medicinal Value. Plants 2020, 9, 1408. [Google Scholar] [CrossRef] [PubMed]
- Park, J.E.; Kim, J.Y.; Kim, J.; Kim, Y.J.; Kim, M.J.; Kwond, S.W.; Kwona, O. Pomegranate vinegar beverage reduces visceral fat accumulation in association with AMPK activation in overweight women: A double-blind, randomized, and placebo- controlled trial. J. Funct. Foods 2014, 8, 274–81. [Google Scholar] [CrossRef]
- Mitrou, P.; Petsiou, E.; Papakonstantinou, E.; Maratou, E.; Lambadiari, V.; Dimitriadis, P.; Spanoudi, F.; Raptis, S.A.; Dimitriadis, G. Vinegar Consumption Increases Insulin- Stimulated Glucose Uptake by the Forearm Muscle in Humans with Type 2 Diabetes. J. Diabetes Res. 2015, 2015, 175204. [Google Scholar] [CrossRef] [PubMed]
- Khezri, S.S.; Saidpour, A.; Hosseinzadeh, N.; Amiri, Z. Beneficial Effects of Apple Cider Vinegar on Weight Management, Visceral Adiposity Index and Lipid Profile in Overweight or Obese Subjects Receiving Restricted Calorie Diet: A Randomized Clinical Trial. J. Funct. Foods 2018, 43, 95. [Google Scholar] [CrossRef]
- Arjmandfard, D.; Behzadi, M.; Sohrabi, Z.; Mohammadi Sartang, M. Effects of Apple Cider Vinegar on Glycemic Control and Insulin Sensitivity in Patients with Type 2 Diabetes: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of Controlled Clinical Trials. Front. Nutr. 2025, 12, 1528383. [Google Scholar] [PubMed]
- Tehrani, S.D.; Keshani, M.; Rouhani, M.H.; Moallem, S.A.; Bagherniya, M.; Sahebkar, A. The Effects of Apple Cider Vinegar on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials. Curr. Med. Chem. 2025, 32, 2257–2274. [Google Scholar] [CrossRef] [PubMed]
- Ramírez-Zacarías, J.L.; Castro-Muñozledo, F.; Kuri-Harcuch, W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 1992, 97, 493–7. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.H.; Cho, H.D.; Jeong, J.H.; Lee, M.K.; Jeong, Y.K.; Shim, K.H.; Seo, K.I. New vinegar produced by tomato suppresses adipocyte differentiation and fat accumulation in 3T3-L1 cells and obese rat model. Food Chem. 2013, 141, 3241–9. [Google Scholar] [CrossRef] [PubMed]
- Son, H.K.; Kim, Y.K.; Shin, H.W.; Lim, H.J.; Moon, B.S.; Lee, J.J. Comparison of Anti- obesity Effects of Spirit Vinegar and Natural Fermented Vinegar Products on the Differentiation of 3T3-L1 Cells and Obese Rats Fed a High-fat Diet. J. Food Nutr. Res. 2017, 5, 594–605. [Google Scholar]
- Paar, M.; Jüngst, C.; Steiner, N.A.; Magnes, C.; Sinner, F.; Kolb, D.; Lass, A.; Zimmermann, R.; Zumbusch, A.; Kohlwein, S.D.; et al. Remodeling of lipid droplets during lipolysis and growth in adipocytes. J. Biol. Chem. 2012, 287, 11164–73. [Google Scholar] [CrossRef] [PubMed]
- Listenberger, L.L.; Han, X.; Lewis, S.E.; Cases, S.; Farese, R.V., Jr.; Ory, D.S.; Schaffer, J.E. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. U S A. 2003, 100, 3077–82. [Google Scholar] [CrossRef] [PubMed]
- Ábel, T.; Csobod Csajbókné, É. Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control. Int. J. Mol. Sci. 2026, 27, 1186. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.F.; Ruan, C.C.; Lei, Y. PPARgamma Mediates Transdifferentiation of CX3CR1(+)-Derived Cells into Adipocytes. Int. J. Mol. Sci. 2026, 27, 2917. [Google Scholar] [PubMed]
- Hosoda, S.; Kawazoe, Y.; Shiba, T.; Numazawa, S.; Manabe, A. Anti-Obesity Effect of Ginkgo Vinegar, a Fermented Product of Ginkgo Seed Coat, in Mice Fed a High-Fat Diet and 3T3-L1 Preadipocyte Cells. Nutrients 2020, 12, 230. [Google Scholar] [PubMed]
- Barrea, L.; Muscogiuri, G.; Annunziata, G.; Laudisio, D.; Pugliese, G.; Salzano, C.; Colao, A.; Savastano, S. From gut microbiota dysfunction to obesity: could short-chain fatty acids stop this dangerous course? Hormones 2019, 18, 245–250. [Google Scholar] [CrossRef] [PubMed]
- Medjakovic, S.; Hobiger, S.; Jungbauer, A. Pomegranate: High Binding Affinity for PPARγ, a Drug Target for Diabetes Type 2, and Lipid Remodelling in Adipocytes. Nat. Prod. Chem. Res. 2014, 2, 4. [Google Scholar]
- Ok, E.; Do, G.M.; Lim, Y.; Park, J.E.; Park, Y.J.; Kwon, O. Pomegranate vinegar attenuates adiposity in obese rats through coordinated control of AMPK signaling in the liver and adipose tissue. Lipids Health Dis. 2013, 12, 163. [Google Scholar] [CrossRef] [PubMed]
- Du, P.; Song, J.; Qiu, H.; Liu, H.; Zhang, L.; Zhou, J.; Jiang, S.; Liu, J.; Zheng, Y.; Wang, M. Polyphenols Extracted from Shanxi-Aged Vinegar Inhibit Inflammation in LPS-Induced RAW264.7 Macrophages and ICR Mice via the Suppression of MAPK/NF-κB Pathway Activation. Molecules 2021, 26, 2745. [Google Scholar] [PubMed]
- Yang, M.; Wang, Y.; Patel, G.; Xue, Q.; Singor Njateng, G.S.; Cai, S.; Cheng, G.; Kai, G. In vitro and in vivo anti-inflammatory effects of different extracts from Epigynum auritum through down-regulation of NF-κB and MAPK signaling pathways. J. Ethnopharmacol. 2020, 261, 113105. [Google Scholar] [PubMed]
- Kundu, J.K.; Na, H.K.; Chun, K.S.; Kim, Y.K.; Lee, S.J.; Lee, S.S.; Lee, O.S.; Sim, Y.C.; Surh, Y.J. Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells. J. Nutr. 2003, 133((11) Suppl 1, 3805S–3810S. [Google Scholar] [PubMed]
- Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; Wang, X.; Zhao, L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2017, 9, 7204–7218. [Google Scholar] [CrossRef] [PubMed]
- Xu, J.; Zhao, Y.; Aisa, H.A. Anti-inflammatory effect of pomegranate flower in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages. Pharm. Biol. 2017, 55, 2095–2101. [Google Scholar] [PubMed]
- Bindal, A.; Aşçı, H.; Karabacak, P.; Garlı, S.; Kolay, Ö.; Elmas, A.; Bindal, G.T.; Oğuzlar, F.Ç.; Özmen, Ö. Gallic acid attenuates LPS-induced hepatic injury via SIRT-1- dependent immunomodulation and anti-apoptotic mechanisms in rats. Biochim. Biophys. Acta Mol. Basis Dis. 2026, 1872, 168194. [Google Scholar] [PubMed]







| Phytochemical products | Pomegranate vinegar | Prickly pear vinegar | Apple vinegar |
| Total Polyphenols (mg GAE/mL) | 41.09 ± 7.02 | 29.06 ± 3.11 | 38.05 ± 5.25 |
| Oxalic acid (mg/ml) | 1.13 ± 0.08 | 2.21 ± 0.09 | 0.51 ± 0.03 |
| Formic acid (mg/ml) | 0.56 ± 0.01 | ND | ND |
| Ascorbic acid (mg/ml) | 0.52 ± 0.01 | 0.19 ± 0.01 | 0.14 ± 0.01 |
| Acetic acid (mg/ml) | 0.031 ± 0.001 | 0.15 ± 0.01 | 0.05 ± 0.001 |
| Citric acid (mg/ml) | 4.55 ± 0.31 | 0.84 ± 0.01 | 0.13 ± 0.01 |
| Malic acid (mg/ml) | 0.022 ± 0.001 | ND | ND |
| TA (% w/v) | 0.98 ± 0.01 | 0.31 ± 0.02 | 0.73 ± 0.06 |
| Tannins | +++ | - | + |
| Alkaloids | + | + | - |
| Quinones | - | - | - |
| Saponins | +++ | ++ | +++ |
| Anthocyanins | - | - | + |
| Triterpenes | +++ | +++ | ++ |
| Total acidity (% w/v) | 0.97 ± 0.03 | 0.30 ± 0.09 | 0.77 ± 0.08 |
| pH | 2.95 ± 0.0033 | 3.24 ± 0.0033 | 3.28 ± 0.0066 |
| Flavonoids compounds (mg QE)/mL) | |||
| Pomegranate vinegar | Prickly pear vinegar | Apple vinegar | |
| Epigallocatechin gallate | 211 ± 9.64 | 51.9 ± 4.34 | 46.8 ± 3.22 |
| Rutin | 211 ± 8.89 | 26.2 ± 2.71 | 8.45 ± 0.13 |
| Catechin | 148 ± 14.7 | 44.9 ± 3.28 | 107 ± 2.71 |
| Naringenin | 165 ± 0.58 | 76.2 ± 5.31 | 1.84 ± 0.21 |
| Myricetin | 93 ± 6.08 | ND | 22.3 ± 2.12 |
| Hesperidin | 19 ± 3.46 | 76.2 ± 0.31 | ND |
| Quercetin | 13 ± 0.58 | 9.08 ± 0.03 | 33.1 ± 2.09 |
| Gallic acid | 12 ± 2.01 | 2.27 ± 0.07 | 8.52 ± 1.11 |
| Caffeic acid | 20.6 ± 2.22 | 17.4 ± 3.07 | 4.67 ± 0.81 |
| Vanillin | 20.7 ± 1.89 | ND | 53.5 ± 1.77 |
| Benzoic acid | 97.6 ± 5.33 | 13.2 ± 0.99 | ND |
| Salicylic acid | ND | ND | 2.37 ± 0.09 |
| Parameters/Groups | Group I | Group II | Group III | Group IV | ||
| LSD-controlled | HFD-controlled | HFD-FVs-treated | HFD-Placebo | |||
| PGV | PPV | AV | ||||
| Body weight (g) | 80 ± 9 | 147 ± 12*** | 81 ± 4***/¶¶¶ | 84 ± 3***/¶¶¶ | 102 ± 7***/¶¶¶ | 142 ± 8*** |
| BMI (g/cm2) | 0.39 ± 0.02 | 0.48 ± 0.02*** | 0.32 ± 0.01ns/¶¶¶ | 0.36 ± 0.04ns/¶¶¶ | 0.43 ± 0.06ns/¶¶¶ | 0.46 ± 0.01*** |
| Total visceral fat (mg/g BW) | 10.3 ± 3.38 | 25.8 ± 4.32*** | 14.2 ± 1.85***/¶¶¶ | 15.1 ± 2.05***/¶¶¶ | 18.7 ± 2.11***/¶¶¶ | 26.3 ± 4.38*** |
| Retroperitoneal fat (mg/g BW) | 2.75 ± 0.66 | 3.02 ± 0.57ns | 1.66 ± 0.44 ns/ns | 1.82 ± 0.21 ns/ns | 1.97 ± 0.33ns/ns | 2.98 ± 0.75ns |
| Omental fat (mg/g BW) | 1.27 ± 0.91 | 9.95 ± 1.33*** | 5.48 ± 1.08***/¶¶¶ | 6.67 ± 1.04***/¶¶¶ | 6.93 ± 1.06***/¶¶¶ | 10.1 ± 2.22*** |
| Mesenteric fat (mg/g BW) | 6.33 ± 1.81 | 12.9 ± 2.42*** | 7.11 ± 0.23***/¶¶¶ | 8.18 ± 0.72***/¶¶¶ | 8.91± 0.55***/¶¶¶ | 13.2 ± 1.41*** |
| Epididymal fat (mg/g BW) | 3.14 ± 0.72 | 8.69 ± 1.47*** | 4.78 ± 0.15*** | 5.39 ± 0.22*** | 6.25 ± 0.66*** | 9.02 ± 0.73*** |
| Subcutaneous fat (mg/g BW) | 1.93 ± 0.17 | 8.33 ± 1.18*** | 4.59 ± 0.25***/¶¶¶ | 5.17 ± 0.33***/¶¶¶ | 6.09 ± 0.44***/¶¶¶ | 7.92 ± 0.22*** |
| Perirenal fat (mg/g BW) | 2.13 ± 0.51 | 2.82 ± 1.61ns | 2.22 ± 0.31 ns/ns | 2.55 ± 0.42 ns/ns | 2.72 ± 0.55 ns/ns | 2.57 ± 1.91ns |
| Suprascapular fat (mg/g BW) | 5.91 ± 2.14 | 12.5 ± 1.08** | 6.88 ± 1.33***/¶¶¶ | 7.75 ± 2.55***/¶¶¶ | 8.63 ± 3.11***/¶¶¶ | 11.9 ± 2.01** |
| Gonadal fat (mg/g BW) | 1.78 ± 0.61 | 1.93 ± 0.22ns | 1.26 ± 0.55 ns/ns | 1.65 ± 0.77 ns/ns | 1.76 ± 0.38 ns/ns | 1.86 ± 1.24ns |
| Intramuscular fat (mg/g BW) | 2.51 ± 0.33 | 3.74 ± 0.27** | 2.06 ± 0.24***/¶¶¶ | 2.32 ± 0.55***/¶¶¶ | 2.81 ± 0.77***/¶¶¶ | 3.67 ± 0.45** |
| Adiposity index (% BW) | 2.61 ± 0.35 | 3.87 ± 0.95*** | 2.69 ± 0.11**/¶¶¶ | 2.81 ± 0.09**/¶¶¶ | 2.97 ± 0.17**/¶¶¶ | 3.91 ± 0.47*** |
| Brown adipose tissue (mg/g BW) | 0.46 ± 0.03 | 0.33 ± 0.07* | 0.55 ± 0.03*//¶ | 0.43 ± 0.04*//¶ | 0.47 ± 0.05*//¶ | 0.31 ± 0.02* |
| Parameters / Groups | Group I | Group II | Group III | Group IV | ||
|---|---|---|---|---|---|---|
| LSD-controlled | HFD-controlled | HFD-FVs-treated | HFD-Placebo | |||
| PGV | PPV | AV | ||||
| Caloric intake (Kcal/100g BW) | 131 ± 1.9 | 534 ± 11*** | 294 ± 35***/¶¶¶ | 332 ± 22***/¶¶¶ | 369 ± 41***/¶¶¶ | 492 ± 17*** |
| Respiratory quotient | 0.913 ± 0.09 | 0.975 ± 0.03ns | 0.753 ± 0.05***/¶¶¶ | 0.709 ± 0.02***/¶¶¶ | 0.699 ± 0.07***/¶¶¶ | 0.944 ± 0.07 ns |
| BMR (mLO2/h/g BW) | 0.521 ± 0.02 | 0.643 ± 0.09*** | 0.972 ± 0.03***/¶¶¶ | 0.887 ± 0.05***/¶¶¶ | 0.842 ± 0.07***/¶¶¶ | 0.675 ± 0.03*** |
| TEE (kJ/kg BW/day) | 1152 ± 27 | 1191 ± 33 | 1726 ± 59***/¶¶¶ | 1643 ± 37***/¶¶¶ | 1560 ± 68***/¶¶¶ | 1189 ± 44 |
| Glucose (mmol / L) | 5.21 ± 0.51 | 15.2 ± 1.04*** | 8.36 ± 1.17ns/¶¶¶ | 9.43 ± 1.22ns/¶¶¶ | 10.5 ± 1.03ns/¶¶¶ | 14.9 ± 1.82*** |
| HbA1c (mmol / mol) | 29.9 ± 0.65 | 98.2 ± 9.44*** | 54.1 ± 3.85ns/¶¶¶ | 60.8 ± 2.77ns/¶¶¶ | 67.8 ± 4.45ns/¶¶¶ | 95.9 ± 7.11*** |
| Insulin (pmol / L) | 110 ± 21 | 580 ± 47*** | 319 ± 24***/¶¶¶ | 360 ± 32***/¶¶¶ | 401 ± 44***/¶¶¶ | 608 ± 85*** |
| HOMA-IR | 3.41 ± 0.14 | 55.4 ± 1.23*** | 30.6 ± 2.11ns/¶¶¶ | 34.4 ± 5.09ns/¶¶¶ | 38.2 ± 4.33ns/¶¶¶ | 56.9 ± 0.44*** |
| ALT (IU/L) | 26.3 ± 1.58 | 74.1 ± 2.35*** | 40.7 ± 3.07 ns/¶¶¶ | 45.9 ± 5.33 ns/¶¶¶ | 51.2 ± 6.41 ns/¶¶¶ | 81.3 ± 1.71*** |
| AST (IU/L) | 86.1 ± 6.7 | 127 ± 25*** | 69.8 ± 21.3***/¶¶¶ | 80.2 ± 11.2***/¶¶¶ | 87.7 ± 12.2***/¶¶¶ | 129 ± 33***/¶¶¶ |
| Triglycerides (mmol / L) | 0.81 ± 0.07 | 4.09 ± 0.61*** | 2.25 ± 0.91***/¶ | 2.54 ± 0.77***/¶ | 1.58 ± 0.01***/¶ | 3.07 ± 0.06*** |
| Total cholesterol (mmol / L) | 1.48 ± 0.70 | 8.06 ± 1.22*** | 4.44 ± 0.64***/¶¶¶ | 5.01 ± 0.22***/¶¶¶ | 2.81 ± 0.64***/¶¶¶ | 7.98 ± 1.15*** |
| NEFA (μmol / L) | 291 ± 33 | 578 ± 41*** | 318 ± 66***/¶¶¶ | 359 ± 25***/¶¶¶ | 298 ± 77***/¶¶¶ | 609 ± 23*** |
| Hs-CRP (mg/L) | 5.90 ± 1.11 | 18.1 ± 1.33*** | 9.33 ± 1.54***/¶¶¶ | 11.1 ± 2.09***/¶¶¶ | 12.5 ± 3.04***/¶¶¶ | 16.45 ± 1.23***/¶¶¶ |
| Fibrinogen (g/L) | 2.27 ± 0.15 | 3.04 ± 0.27* | 1.68 ± 0.07*/¶ | 1.89 ± 0.09*/¶ | 2.15 ± 0.03*/¶ | 3.11 ± 0.19*/¶ |
| tHcy (µmol/L) | 7.2 ± 2.52 | 21.1 ± 3.53*** | 11.6 ± 4.33***/¶¶¶ | 13.1 ± 2.44***/¶¶¶ | 14.6 ± 1.77***/¶¶¶ | 19.3 ± 4.11***/¶¶¶ |
| Total hepatic lipids (g 100 g wet/wt) | 2.97 ± 0.31 | 6.17 ± 0.94*** | 3.41 ± 0.66***/¶¶¶ | 3.83 ± 0.54***/¶¶¶ | 4.26 ± 0.72***/¶¶¶ | 5.83 ± 0.76*** |
| Hepatic glycogen (g/100 g wet/wt) | 2.77 ± 0.84 | 2.44 ± 0.93* | 3.93 ± 0.18***/¶¶¶ | 3.36 ± 0.22***/¶¶¶ | 3.19 ± 0.32***/¶¶¶ | 2.65 ± 0.79 |
| Liver mass (% body BW) | 2.51 ± 0.45 | 4.05 ± 0.78*** | 2.23 ± 0.47***/¶¶¶ | 2.52 ± 0.33***/¶¶¶ | 2.89 ± 0.33***/¶¶¶ | 3.64 ± 1.49*** |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).